Tom Plitz recently served as Chief Executive Officer of Chord Therapeutics SA, a privately held biopharmaceutical firm based in Geneva, Switzerland, which was acquired by Merck KGaA in January 2022 for an undisclosed amount. He has more than two decades of experience in pharmaceutical R&D. Prior to Chord, he was Chief Scientific Officer of the rare disease company, Wilson Therapeutics, which was acquired by Alexion Pharmaceuticals for US $855 million in April 2018. Tom’s previous experience includes senior roles at Serono, Merck, and Shire Pharmaceuticals, where he worked across multiple therapeutic areas, including neuroinflammatory, metabolic, and rare diseases.

Tom holds Ph.D. and M.S. degrees from Technical University of Munich, Germany.